A significant proportion of patients with COVID-19 develop acute respiratory distress syndrome (ARDS) with high risk of death. The efficacy of veno-venous extracorporeal membrane oxygenation (VV-ECMO) for COVID-19 on longer-term outcomes, unlike in other viral pneumonias, is unknown. In this study, we aimed to compare the 6 month mortality of patients receiving VV-ECMO support for COVID-19 with a historical viral ARDS cohort. Fifty-three consecutive patients with COVID-19 ARDS admitted for VV-ECMO to the Royal Brompton Hospital between March 17, 2020 and May 30, 2020 were identified. Mortality, patient characteristics, complications, and ECMO parameters were then compared to a historical cohort of patients with non-COVID-19 viral pneumonia. At 6 months survival was significantly higher in the COVID-19 than in the non-COVID-19 viral pneumonia cohort (84.9% vs. 66.0%, p = 0.040). Patients with COVID-19 had an increased Murray score (3.50 vs. 3.25, p = 0.005), a decreased burden of organ dysfunction (sequential organ failure score score [8.76 vs. 10.42, p = 0.004]), an increased incidence of pulmonary embolism (69.8% vs. 24.5%, p < 0.001) and in those who survived to decannulation longer ECMO runs (19 vs. 11 days, p = 0.001). Our results suggest that survival in patients supported with EMCO for COVID-19 are at least as good as those treated for non-COVID-19 viral ARDS.
Extracorporeal membrane oxygenation (ECMO) can support patients with severe cardiorespiratory failure presenting with hypoxia who would otherwise have not survived. Patient selection for ECMO is challenging and relies on the integration of physiological variables with an assessment of reversibility of the underlying condition or suitability for transplantation. In this review, we focus on patients with cardiorespiratory disease who may present with severe hypoxia. We will discuss the indications and contraindications for ECMO; the evidence for ECMO, which is limited to a small number of clinical trials and registry data; the complications of ECMO; expanding technologies and indications; the development of a multidisciplinary ECMO network; and future research. The aim is to increase knowledge of this important area for respiratory physicians.
OBJECTIVES: Early studies of venovenous extracorporeal membrane oxygenation (ECMO) in COVID-19 have revealed similar outcomes to historical cohorts. Changes in the disease and treatments have led to differences in the patients supported on venovenous ECMO in the first and second waves. We aimed to compare these two groups in both the acute and follow-up phase. DESIGN: Retrospective single-center cohort study comparing mortality at censoring date (November 30, 2021) and decannulation, patient characteristics, complications and lung function and quality of life (QOL—by European Quality of Life 5 Dimensions 3 Level Version) at first follow-up in patients supported on venovenous ECMO between wave 1 and wave 2 of the COVID-19 pandemic. SETTING: Critical care department of a severe acute respiratory failure service. PATIENTS: Patients supported on ECMO for COVID-19 between wave 1 (March 17, 2020, to August 31, 2020) and wave 2 (January 9, 2020, to May 25, 2021). INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: One hundred twenty-three patients were included in our analysis. Survival at censoring date (χ2, 6.35; p = 0.012) and decannulation (90.4% vs 70.0%; p < 0.001) was significantly lower in the second wave, while duration of ECMO run was longer (12.0 d [18.0–30.0 d] vs 29.5 d [15.5–58.3 d]; p = 0.005). Wave 2 patients had longer application of noninvasive ventilation (NIV) prior to ECMO and a higher frequency of barotrauma. Patient age and NIV use were independently associated with increased mortality (odds ratio 1.07 [1.01–1.14]; p = 0.025 and 3.37 [1.12–12.60]; p = 0.043, respectively). QOL and lung function apart from transfer coefficient of carbon monoxide corrected for hemoglobin was similar at follow-up across the waves. CONCLUSIONS: Most patients with COVID-19 supported on ECMO in both waves survived in the short and longer term. At follow-up patients had similar lung function and QOL across the two waves. This suggests that ECMO has an ongoing role in the management of a carefully selected group of patients with COVID-19.
Inhaled nitric oxide (iNO) has been reported as a rescue strategy in ARDS. A potential role for iNO is proposed in COVID-19, especially given the ‘pulmonary vascular’ phenotype and right ventricular (RV) dysfunction increasingly apparent in this disease. Patients admitted to a tertiary respiratory failure centre in the UK receiving iNO with at least moderate ARDS in March-May 2020 were studied. Measurements to calculate PaO2/FiO2 ratio, oxygenation index (OI), and dead space fraction (based on the Bohr equation) were obtained before and after initiating iNO from ventilator data. Thirty-five consecutive patients (20% female) were treated with 20 ppm iNO, for 146.4 (80.8) h. PaO2/FiO2 ratio increased from baseline (13.6 [3.9] vs 17.4 [5.5] kPa at 24 hours, p<0.001). OI and dead space fraction were significantly reduced (Figure 1). According to a pre-defined improvement in PaO2/FiO2 ratio by at least 1.33 kPa, 23 patients [65.7%] responded to iNO at 24 h. Responders had higher baseline brain natriuretic peptide (p=0.023) and troponin (p=0.015). The 30 day mortality after starting iNO was 17/35 (48.5%). In this cohort of patients with at least moderately severe COVID-ARDS, iNO at 20 ppm improved oxygenation and ventilatory efficiency. We were able to differentiate responders from non-responders on the basis of higher levels of cardiac biomarkers, suggesting a putative mechanism.
BackgroundEarly studies of veno-venous extracorporeal membrane oxygenation (VV-ECMO) in COVID-19 have revealed similar outcomes to historical cohorts. Changes in the disease and treatments has led to differences in the patients supported on VV-ECMO in the 1st and 2nd waves. We aimed to compare these two groups in both the acute and follow-up phase.MethodsIn this retrospective study, we identified the differences between patients supported on ECMO for COVID-19 between wave 1 (17/03/2020-31/08/2020) and wave 2 (01/09/2020-25/05/2021). We examined mortality at censoring date (30/11/2021) and decannulation, patient characteristics, complications and lung function and quality of life (QOL – by EQ5D3L) at first follow-up.FindingsOne-hundred and twenty-three patients were included in our analysis. Survival at censoring date [Chi-sqaured 6.35, p=0.012] and decannulation [90.4% vs 70.0%, p<0.001], was significantly lower in the 2nd wave, whilst duration of ECMO run was longer [12.0(18.0-30.0) days vs. 29.5(15.5-58.3)] days (p=0.005)). Wave 2 patients had longer application of non-invasive ventilation (NIV) prior to ECMO and a higher incidence of barotrauma. Patient age and NIV use were independently associated with increased mortality [OR 1.07(1.01-1.14), p=0.025 and 3.37(1.12–12.60), p=0.043 respectively]. QOL and lung function, apart from KCOc was similar at follow up across the waves.ConclusionMost patients with COVID-19 supported on ECMO in both waves survived in the short and longer term. At follow-up patients had similar lung function and QOL across the 2 waves. This suggests that ECMO has an ongoing role in the management of a carefully selected group of patients with COVID-19.Trial RegistrationResearch Ethics Committee (20/EM/0204)